Q11 Development and Manufacture of Drug Substances Q & A (Regarding the selection and justification of starting materials)
- Published: Sunday February 26 2017 08: 45
This draft guidance, When finalized, will Represent the current thinking of the Food and Drug Administration (FDA or Agency) is this topic. It Does not suit les Any rights for Any Person and is not binding on FDA or the public. You can use an alternative approach if it satisfying the requirements of the applicable statutes and règlements.
Final Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products
- Published: Thursday January 12 2017 11: 45
This guidance Describes and Explains the final rule on current Good Manufacturing Practice (CGMP) requirements for combination products That FDA Issued on January 22, 2013 (final rule).2 (21 Code of Federal Regulations (CFR) from 4). Prior to issuance of the final rule, ALTHOUGH CGMP règlements Were in place to suit les requirements for drugs, devices, biological products, and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT / Ps), There Were No règlements to Clarify and explain the implementation of These CGMP requirements to combination products. The final rule Did not suit les Any new requirements; It was Intended to Clarify qui CGMP requirements apply When drugs, devices, and biological products are combined to create combination products, and to set forth a transparent and streamlined Regulatory framework for firms to use When Demonstrating compliance with CGMP requirements applicable.
Guideline on validation process for finished products - information and data to be Provided in Regulatory submissions
- Published: Thursday December 8 2016 08: 45
This guideline replaces the previous Note for guidance on process validation (CPMP / QWP / 848 / 96, EMEA / CVMP / 598 / 99). The guideline is brought` into line with ICH Q8, Q9 and Q10 materials and the possibility to use continuous process verification in addition to, or INSTEAD of, traditional process validation Described in the previous guideline has-been added and is Encouraged. This guideline Does not Introduce new requirements on medicinal products already authorized and on the market, aim Clarifies how companies can take advantage of the new possibilities Given When Applying enhanced process understanding coupled with risk management tools under an efficient quality system as described by ICH Q8, Q9 and Q10.
- Published: Thursday January 12 2017 08: 45
Management of documentation and records is one of the pillars of a quality management system (QMS).
Several chapters of the ISO / IEC 17025 4.2 Management system, Document Control 4.3, 4.13 and 5.4.7 Control of records Control of data are dedicated to thesis topics.
Ce document replaces Guideline PA / PH / OMCL (97) 5 and the share of Guideline PA / PH / OMCL (07) 105 DEF related to the archiving of records.
Q11 Implementation Working Group Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological / Biological Entities) Questions and Answers
- Published: Thursday December 8 2016 08: 40
Since the ICH guideline Q11 Was finalised, worldwide experience with implementation of the recommendations on the development and manufacture of drug substances HAS Given rise to requests for clarification Relating to the selection and justification of starting materials. This Question and Answer (Q & A) document est Intended to Provide additional clarification and to Promote convergence on the considerations for the selection and justification of starting materials and on the information Provided That shoulds be in permission marketing applications and / or Master Files. The focus of the Q & A document est one chemical entity drug substances.